Previous 10 | Next 10 |
MedTech firm, Senseonics (NYSE:SENS) joined its partner Ascensia Diabetes Care to announce on Wednesday that the first commercial patient has been implanted with Eversense E3, the company’s next-generation continuous glucose monitoring system. The U.S. launch of Eversense E3 comes week...
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, its commercialization partner, have anno...
Today, we take our first look at Senseonics Holdings, a small medical device concern starting to ramp up revenues. Senseonics has the only long term continuous glucose monitoring system on the market and a new upgraded version will be out soon. A full investment analysis follows i...
Recording a significant 40% loss for the trailing 12 months, Senseonics' stock is facing high selling pressures. Senseonics lacks revenue growth consistency and profitability. The company carries several risk factors that highlight the speculative nature of the stock. For fu...
4 Penny Stocks to Watch in March 2022 With March fully underway for trading penny stocks and blue chips, there is a lot for investors to consider right now. As we know, the largest impacting factor on the stock market is the invasion of Ukraine by Russia. This has resulted in major vola...
Senseonics Holdings, Inc. (SENS) Q4 2021 Results Conference Call March 01, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Tim Goodnow - President, CEO Nick Tressler - CFO Conference Call Participants Chris Pasquale - Guggenheim Jayson Bedford - Raymond James Marie Thibau...
Glucose monitoring system manufacturer Senseonics Holdings (NYSE:SENS) swung to Q4 2021 net income amidst a modest increase in revenue. The company also set net revenue guidance for 2022 of $14M-$18M, below consensus guidance of $18.74M. Net income was $84.4M ($0.19 per share) in Q4 2021, com...
Senseonics press release (NYSE:SENS): FY GAAP EPS of -$0.72 beats by $0.22. Revenue of $13.67M beats by $0.05M. Shares -2.8%. FY 2022 Guidance: Global net revenue to Senseonics for the full year 2022 is expected to be in the range of $14.0 million to $18.0 million vs. consensus of $18.74 mill...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended...
3 Things Penny Stocks Traders Need to Know in 2022 If you’re looking to trade penny stocks in 2022, it can be challenging. But, with the right information by your side, trading penny stocks right now can be much easier than previously imagined. Now, there are a few ways to ha...
News, Short Squeeze, Breakout and More Instantly...
Senseonics Holdings Inc. Company Name:
SENS Stock Symbol:
NYSE Market:
Senseonics Holdings Inc. Website:
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2024 financial res...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced business updates and provided its full year 2024 financial out...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the A...